Compare Novartis AG (NVS) vs Remitly Global Inc (RELY) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

RELY trades at $24.83, down 5.12% over 24 hours, with a bearish technical signal but strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.93 significantly exceeding expectations of $0.12. Revenue growth is accelerating, reaching $1.64 billion in 2025, with net income turning positive at $67.93 million. A recent partnership with Etsy expands its payment provider reach, signaling business expansion. Analyst consensus is overwhelmingly bullish with a $31.17 price target, representing 25.5% upside from current levels.

The outlook for RELY is positive given its strong revenue trajectory, improving profitability, and strategic partnerships. Key opportunities include continued market share gains in digital remittances and new monetization avenues. Risks involve competitive pressures in fintech, reliance on economic conditions affecting remittance volumes, and potential volatility despite institutional backing. The stock's current pullback may offer a entry point, but investors should weigh execution risks against growth potential.